Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

Sales: The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and ...

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus ...

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

Reports Q4 revenue $1.11B, consensus $1.10B. “In 2024, we implemented our largest US commercial sales force expansion, had two major product ...

Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...

Dexcom stock stock recovered Friday after the diabetes devices maker missed fourth-quarter profit expectations.

We recently published a list of the 10 Best Medical Device Stocks To Buy According to Hedge Funds. In this article, we are ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...